Tirzepatide - PubMed
4 hours ago
- #Obesity Treatment
- #Type 2 Diabetes
- #Tirzepatide
- Tirzepatide is the first dual agonist of GIP and GLP-1 receptors for treating type 2 diabetes and/or obesity.
- It shows dose- and duration-dependent efficacy, reducing HbA1c by 20.4-28.2 mmol/mol and weight by 5-20.9% over 72 weeks.
- Mechanisms include improved insulin sensitivity, delayed gastric emptying, and modulation of food intake centers.
- Safety profile involves gastrointestinal side effects with a 4-10% treatment discontinuation rate.
- Benefits extend to cardiovascular risk factors like lipid profile and anti-inflammatory biomarkers.
- Optimal treatment requires gradual dose escalation and individualized approaches.